Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTA-C1-INH for Acute Hereditary Angioedema Attacks
NCT06361537Phase 3Recruiting
- Sponsor
- Octapharma
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of C1 esterase inhibitor human in hereditary angioedema (HAE), sponsored by Octapharma. Started Apr 2024; status: recruiting.
02
Drugs
C1 esterase inhibitor human
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06361537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361537.